CD98 antibody | knockout validation | TransGenic Inc. KS129
DOI
//dx.doi.org/10.13070/ko.en.6.1799
Date
2016-11-08

This is a knockout-validated antibody summary, based on the publication "Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal

Company: TransGenic Inc.

Antibody: CD98

Catalog number: KS129

Summary: Mouse monoclonal raised against a human cancer cell line. Reacts with human CD98.

Validation Method

Immunofluorescence

Sample

Wild-type and CD98 -/- LS174T cells.

Fixed with 3% paraformaldehyde and permeabilised with 0.2% Triton X-100 in PBS.

Blocking agent

Not stated.

Primary incubation

1:1000 dilution for 1 hour at room temperature.

Secondary incubation

1:1000 dilution of FluoProbe488-conjugated anti-mouse antibody (FP-SA 4110-T, Interchim).

Detection

Leica SP5 confocal microscope with LS AF and Image J software.

Figure

Figure 1 from the article [1].

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Cormerais Y, Giuliano S, Lefloch R, Front B, Durivault J, Tambutte E, et al. Genetic disruption of the multifunctional CD98/LAT1 complex demonstrates the key role of essential amino acid transport in the control of mTORC1 and tumor growth. Cancer Res. 2016;: pubmed